e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 9

Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy

Michael J. Corley; Varun B. Dwaraka; Alina P.S. Pang; Danielle E. Labbato; Ryan Smith; Allison Ross Eckard; Grace A. McComsey · 2026 · Nature Communications

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists have attracted interest as gerotherapeutics, yet clinical-trial evidence for their effects on biological aging is lacking. We report a post hoc exploratory epigenetic age analysis of a 32-week, randomized, double-blind, placebo-controlled phase 2b trial (NCT04019197) of semaglutide in adults with human immunodeficiency virus (HIV)-associated lipohypertrophy (semaglutide n = 45; placebo n = 39). The parent trial's primary endpoint was change in visceral adipose tissue, with secondary cardiometabolic and body-composition endpoints; epigenetic agi

Abstract by Michael J. Corley; Varun B. Dwaraka; Alina P.S. Pang; Danielle E. Labbato; Ryan Smith; Allison Ross Eckard; Grace A. McComsey, Nature Communications (2026) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1038/s41467-026-72861-3